Androgen deprivation therapy for prostate cancer

Eric A. Singer, Dragan J. Golijanin, Hiroshi Miyamoto, Edward M. Messing

Research output: Contribution to journalReview articlepeer-review

Abstract

Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.

Original languageEnglish (US)
Pages (from-to)211-228
Number of pages18
JournalExpert opinion on pharmacotherapy
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2008

Keywords

  • Androgen deprivation
  • Antiandrogen
  • Combined androgen blockade
  • Hormonal therapy
  • Intermittant androgen deprivation
  • Luteinizing hormone releasing hormone
  • Prostate cancer
  • Side effect

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Androgen deprivation therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this